Short answer
Gilead Sciences (GILD) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $8.3B (up 6.8% year over year) with net income of $2.4B.
Q3 2026 key financials · XBRL
- Revenue
- $8.3B
- +6.8% YoY · +6.4% QoQ
- Net income
- $2.4B
- −20.4% YoY · +123.2% QoQ
- Operating margin
- 41.7%
- EPS (diluted)
- $1.95
- −19.8% YoY · +123.1% QoQ
Source: XBRL data from the Gilead Sciences (GILD) Q3 2026 10-Q on SEC EDGAR. USD.
Gilead Sciences Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Third-quarter revenue $8.3B, up 7% YoY from $7.769B
- Product gross margin 81.0% vs 78.6% YoY
- Best segment HIV: $6.2B, up 18%; worst Veklury: $86M, down 69%
- Operating cash flow $11.152B versus $6.692B; cash and equivalents $6.4B
- Near-term headwinds: competitive Cell Therapy demand, lower COVID hospitalizations, $1.75B Trodelvy IPR&D impairment
Risk Factors
- New pricing risk: Biktarvy selected for Medicare Maximum Fair Price, effective January 2028, with CMS completing price-setting in October 2026
- Regulatory risk: 100% tariffs on patented pharmaceuticals began taking effect in July 2026, subject to exemptions and potential modifications
- Clinical-development risk: Phase 3 EVOKE-03 discontinued in June 2026, triggering an impairment charge
- Operational risk: CAR T-cell manufacturing delays or quality issues could constrain Yescarta and Tecartus supply
- Financial risk: $32 billion U.S. investment through 2030 could increase capital expenditures, operating expenses and cash-flow variability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Gilead Sciences quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.